Braintrain 20:20, a Sheffield, UK-based consumer personalized health device manufacturer specializing in sleep aid technologies, raised £485k in seed funding.
Backers included Mercia Fund Management and senior sleep specialists and healthcare entrepreneurs.
The company intends to use the funds to expand the business and complete a formal clinical trial.
Led by Richard Mills, CEO, Braintrain 20:20 provides SleepCogni, a patented product that measures heart rate, skin temperature and oxygen levels in the blood to build a sleep program based entirely around the patient, their habits and their needs. It then delivers cognitive behaviour therapy (CBT) via light and sound therapy though a bedside device and speaker system, which is capable of both inducing sleep and rousing the patient at an appropriate time.
FinSMEs
14/10/2016